# Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-ceritinib-450-mg-d-or-600-mg-d-with-food-versus-750-mg-d/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Byoung Chul Cho,Radka Obermannová,Alessandra Bearz,Mark J. McKeage,Dong-Wang Kim,Ullas Batra,Gloria Borra,Sergey Orlov,Sang-We Kim,Sarayut Lucien Geater,Pieter E. Postmus,Scott A. Laurie,Keunchil Park,Cheng‐Ta Yang,Andrea Ardizzoni,Anna Bettini,Gilberto de Castro,Flavia Kiertsman,Zhe Chen,Yvonne Lau,Kalyanee Viraswami-Appanna,Vanessa Q. Passos,Rafał Dziadziuszko |
| Citations | 72 |
| DOI | 10.1016/j.jtho.2019.03.002 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.jto.org/article/S1556086419301959/pdf |
| OpenAlex ID | https://openalex.org/W2920658753 |
| PMID | 30851442 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Ullas Batra](https://scholariq.org/researchers/ullas-batra/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.